All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 172 of 206 pages ‹ First < 170 171 172 173 174 > Last ›
HSL2003
Becel B, Bardelay D
A french physician's network monitoring medical representatives
Prescrire 1997 Jun
HSL6747
Vitry A, Mansfield P.
Re: breaches of the APMA Code of Conduct
1997 Jun;
HSL8186
Employer/employee relations committee
Carolina Journal of Pharmacy 1997 Jun-Aug;77:6-7
HSL8233
Cohen MR.
Call for an end to unsafe abbreviations in journal ads
Hospital Pharmacy 1997 Jun;32:835-836
HSL6744
Advertisements for donepezil (Aricept) in the BMJ [Editor's response]
BMJ 1997 May 24;314:1556
http://bmj.com/cgi/content/full/314/7093/1555
HSL6745
Gray S.
Advertisements for donepezil (Aricept) in the BMJ: Advertisement suggests an unrealistic improvement in mental status
BMJ 1997 May 24;314:1555
http://bmj.com/cgi/content/full/314/7093/1555
HSL6746
Wagner N.
Advertisements for donepezil (Aricept) in the BMJ: Local committee has declined to approve NHS hospital prescription of donepezil.
BMJ 1997 May 24;314:(7093):1555-6
http://bmj.com/cgi/content/full/314/7093/1555
HSL556
Horton R.
Sponsorship, authorship, and a tale of two media.
Lancet 1997 May 17;349:(9063):1411-2
HSL8324
Lisi DM.
Ethical issues for pharmacists in managed care.
Am J Health Syst Pharm 1997 May 1;54:(9):1041-2,
http://www.ajhp.org/cgi/reprint/54/9/1041
HSL1894
Lexchin J.
What information do physicians receive from pharmaceutical representatives?
Can Fam Physician 1997 May;43:941-5
HSL6738
Beaufour-Ipsen’s promotion of Smecta (smectite)
MaLAM International News 1997 May-Jun;15:(5-6):1-2
HSL6739
Health and medical reporting: PMAC sponsored medical journalism program
PMAC News 1997 May-Jun;6
HSL6740
MaLAM complaints to the APMA
MaLAM Australian News 1997 May-Jun;5:(5-6):1
HSL6741
MaLAM letter follow up—Rhone Poulenc Rorer’s promotion of Flagyl (metronidazole)
MaLAM International News 1997 May-Jun;15:(5-6):2
HSL6742
Program update
PMAC News 1997 May-Jun;8-9
HSL6743
Servier resists but MaLAM persists!
MaLAM Australian News 1997 May-Jun;5:(5-6):2
HSL8242
Janssen tops list of '96 nursing home sales leaders; Glaxo first in total US sales, Novartis first in global sales
Consultant Pharmacist 1997 May;12:610
HSL19992
Derby RA, Peabody JW, Bickel SR, Lawson JS
Cost of drugs in Australia's pharmaceutical benefit scheme
JAMA 1997 Apr 23;277:(16):1277
http://jama.ama-assn.org/content/277/16/1277.1.short
HSL529
Raveendran R, Gitanjali B.
Conflict of interest.
Lancet 1997 Apr 19;349:(9059):1173-4
http://www.thelancet.com/search/results?search_searchuri=%2Fsearch%2Fadvanced&search_resulturi=%2Fsearch%2Fresults&search_preview=no&search_reqfirst=1&search_reqcount=20&search_submode=advanced&update_search=no&search_mode=platform&search_cluster=phoenix&search_text1=Raveendran+R+&search_within1=au&search_operator1=and&search_text2=Gitanjali+B&search_within2=au&search_operator2=and&search_text3=&search_within3=all&restrictterm_lancet=lancet&restrictname_lancet=lancet&restricttype_lancet=journal&restrictdesc_lancet=The+Lancet&restrictname_laneur=laneur&restricttype_laneur=journal&restrictdesc_laneur=The+Lancet+Neurology&restrictname_laninf=laninf&restricttype_laninf=journal&restrictdesc_laninf=The+Lancet+Infectious+Diseases&restrictname_lanonc=lanonc&restricttype_lanonc=journal&restrictdesc_lanonc=The+Lancet+Oncology&search_dateradio=combo&search_datecombo=0%3AALL&search_monthstartcombo=1&search_yearstart=1996&search_monthendcombo=1&search_yearend=2005&search_wordsexactly=yes&search_sort=relevance&Submit=Search
HSL537
McCarthy M.
Sponsors lose fight to stop thyroxine study publication.
Lancet 1997 Apr 19;349:(9059):1149
http://www.thelancet.com/search/results?search_searchuri=%2Fsearch%2Fadvanced&search_resulturi=%2Fsearch%2Fresults&search_preview=no&search_reqfirst=1&search_reqcount=20&search_submode=advanced&update_search=no&search_mode=platform&search_cluster=phoenix&search_text1=McCarthy+M&search_within1=au&search_operator1=and&search_text2=Sponsors&search_within2=ti&search_operator2=and&search_text3=&search_within3=all&restrictterm_lancet=lancet&restrictname_lancet=lancet&restricttype_lancet=journal&restrictdesc_lancet=The+Lancet&restrictname_laneur=laneur&restricttype_laneur=journal&restrictdesc_laneur=The+Lancet+Neurology&restrictname_laninf=laninf&restricttype_laninf=journal&restrictdesc_laninf=The+Lancet+Infectious+Diseases&restrictname_lanonc=lanonc&restricttype_lanonc=journal&restrictdesc_lanonc=The+Lancet+Oncology&search_dateradio=combo&search_datecombo=0%3AALL&search_monthstartcombo=1&search_yearstart=1997&search_monthendcombo=12&search_yearend=1997&search_wordsexactly=yes&search_sort=relevance&Submit=Search
HSL555
Horton R.
Conflicts of interest in clinical research: opprobrium or obsession?
Lancet 1997 Apr 19;349:(9059):1112-3
HSL8245
Kay A.
State of the art. Part 1. Generic medicines
Pharmaceutical Journal 1997 Apr 19;258:554-559
HSL569
Deyo RA, Psaty BM, Simon G, Wagner EH, Omenn GS.
The messenger under attack -- intimidation of researchers by special-interest groups.
N Engl J Med 1997 Apr 17;336:(16):1176-80
HSL527
Rennie D.
Thyroid storm.
JAMA 1997 Apr 16;277:(15):1238-43
HSL565
Eckert CH.
Bioequivalence of levothyroxine preparations: industry sponsorship and academic freedom.
JAMA 1997 Apr 16;277:(15):1200-1
HSL568
Dong BJ, Hauck WW, Gambertoglio JG, Gee L, White JR, Bubp JL, Greenspan FS.
Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism.
JAMA 1997 Apr 16;277:(15):1205-13
HSL575
Blumenthal D, Campbell EG, Anderson MS, Causino N, Louis KS.
Withholding research results in academic life science. Evidence from a national survey of faculty
JAMA. 1997 Apr 16;277:(15):1224-8
HSL20393
Shaughnessy AF
Patient-Oriented Evidence That Matters: POEMS
EJHP 1997 Apr 15;126:(8):667
http://www.google.com.au/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CCcQFjAA&url=http%3A%2F%2Fwww.essentialevidenceplus.com%2Farticles%2FEJHP_Feb04p64.pdf&ei=bHh-UMetBI2zrAel54CABA&usg=AFQjCNHxJWkt04BVh5TJgARYiYn9ZjDd-w
HSL530
Rapp MS.
Can drug companies have it both ways?
CMAJ 1997 Apr 1;156:(7):982-3
http://www.cmaj.ca/cgi/reprint/156/7/982
HSL6720
Lexchin J.
Consequences of direct-to-consumer advertising of prescription drugs.
Can Fam Physician 1997 Apr;43:594-6,:
HSL8244
Wechsler J.
Who's going to pick up FDA's user fee tab?
Managed Healthcare 1997 Apr;7:17
HSL8246
Southwick K.
Battling allergy therapies focus on consumer choice
Managed Healthcare 1997 Apr;7:54-58
HSL8326
Wechsler J.
Washington report: Congress debates FDA fees and funding
Pharmaceutical Technology 1997 Apr;21:16, 18, 20, 22, 24, 26, 28
HSL19799
Stix G
The Ties That Bind: A study of journal publications details investigators' financial interests in their research
Scientific American 1997 Mar 17
http://www.scientificamerican.com/article.cfm?id=the-ties-that-bind
HSL515
Sukkari SR.
Weighing benefits and risks of drug to treat obesity.
CMAJ 1997 Mar 15;156:(6):768-9
http://www.cmaj.ca/cgi/reprint/156/6/768
HSL551
Judge R.
Dangers of fluoxetine.
Lancet 1997 Mar 15;349:(9054):809
HSL516
Stone LR.
Editorials and conflicts of interest.
N Engl J Med 1997 Mar 6;336:(10):728
http://content.nejm.org/cgi/search?andorexactfulltext=and&andorexacttitleabs=and&excludeflag=TWEEK_element&search_tab=authors&searchtitle=Authors&hits=20&author1=Stone+LR&sendit=GO&author2=&fulltext=&sortspec=Score+desc+PUBDATE_SORTDATE+desc&fmonth=Aug&fyear=1995&tmonth=Aug&tyear=2005&tocsectionid=Original+Articles&tocsectionid=Special+Reports&tocsectionid=Special+Articles&tocsectionid=Images+in+Clinical+Medicine&tocsectionid=Clinical+Practice&tocsectionid=Case+Records+of+the+Massachusetts+General+Hospital&tocsectionid=Review+ArticlesAORBClinical+PracticeAORBClinical+Implications+of+Basic+ResearchAORBMolecular+Medicine&tocsectionid=Clinical+Problem-Solving&tocsectionid=EditorialsAORBPerspectiveAORBOutlookAORBBehind+the+Research&tocsectionid=Legal+Issues+in+Medicine&tocsectionid=Sounding+BoardAORBClinical+Debate&tocsectionid=Correspondence&tocsectionid=Clinical+Implications+of+Basic+Research&tocsectionid=Book+Reviews&tocsectionid=Health+Policy*AORBQuality+of+Health+Care&tocsectionid=Occasional+Notes
HSL526
Salzman R.
Editorials and conflicts of interest.
N Engl J Med 1997 Mar 6;336:(10):728
http://content.nejm.org/cgi/search?andorexactfulltext=and&andorexacttitleabs=and&excludeflag=TWEEK_element&search_tab=authors&searchtitle=Authors&hits=20&author1=Salzman+R&sendit=GO&author2=&fulltext=&sortspec=Score+desc+PUBDATE_SORTDATE+desc&fmonth=Feb&fyear=1997&tmonth=Apr&tyear=1997&tocsectionid=Original+Articles&tocsectionid=Special+Reports&tocsectionid=Special+Articles&tocsectionid=Images+in+Clinical+Medicine&tocsectionid=Clinical+Practice&tocsectionid=Case+Records+of+the+Massachusetts+General+Hospital&tocsectionid=Review+ArticlesAORBClinical+PracticeAORBClinical+Implications+of+Basic+ResearchAORBMolecular+Medicine&tocsectionid=Clinical+Problem-Solving&tocsectionid=EditorialsAORBPerspectiveAORBOutlookAORBBehind+the+Research&tocsectionid=Legal+Issues+in+Medicine&tocsectionid=Sounding+BoardAORBClinical+Debate&tocsectionid=Correspondence&tocsectionid=Clinical+Implications+of+Basic+Research&tocsectionid=Book+Reviews&tocsectionid=Health+Policy*AORBQuality+of+Health+Care&tocsectionid=Occasional+Notes
HSL567
Douglas EF.
Editorials and conflicts of interest.
N Engl J Med 1997 Mar 6;336:(10):728
HSL576
Blank NK.
Editorials and conflicts of interest.
N Engl J Med 1997 Mar 6;336:(10):728-9
HSL559
Heagerty AM.
Industry-sponsored research.
Lancet 1997 Mar 1;349:(9052):588
HSL5336
Guell RC.
Haggling for a patent: what a government would have to pay for prescription drug patents.
Health Econ 1997 Mar-Apr 01;6:(2):179-85
http://www3.interscience.wiley.com/cgi-bin/abstract/14638/ABSTRACT
HSL392
Lexchin J.
[Pharmaceutic regulation and inadequate drug prescription in Canada: the case of psychotropic drugs in the 1960s and early 1970s]
Sante Ment Que. 1997 Spring;22:(1):283-300
HSL6728
Sacristan JA, Bolanos E, Hernandez JM, Soto J, Galende I.
Publication bias in health economic studies.
Pharmacoeconomics 1997 Mar;11:(3):289-92
HSL6735
APMA’s revised Code still inadequate
MaLAM Australian News 1997 Mar-Apr;5:(3-4):1-4
HSL6736
Knowledge is the best medicine: campaign update
PMAC News 1997 Mar-Apr;5-6
HSL8232
Poovala S, Banahan B, Kolassa M.
Marketing smart: what makes your MCO tick?
Pharmaceutical Executive 1997 Mar;17:54-56, 58, 60, 62
HSL6734
Avoid financial 'correctness'.
Nature. 1997 Feb 6;385:(6616):469
HSL522
Shapiro MF.
Regulating pharmaceutical advertising: what will work?
CMAJ 1997 Feb 1;156:(3):359-61
http://www.cmaj.ca/cgi/reprint/156/3/359
HSL547
Lexchin J.
Enforcement of codes governing pharmaceutical promotion: what happens when companies breach advertising guidelines?
CMAJ 1997 Feb 1;156:(3):351-6
http://www.cmaj.ca/cgi/reprint/156/3/351
HSL570
Desjardins JG.
The PMAC code of marketing practices: time for improvement? Pharmaceutical Manufacturers Association of Canada
CMAJ 1997 Feb 01;156:(3):363-4
HSL8335
Earl-Slater A.
Regulating the price of the UK's drugs: second thoughts after the government's first report.
BMJ 1997 Feb 1;314:(7077):365-8
http://www.bmj.com/cgi/content/full/314/7077/365
HSL8323
Asplen L.
ASHP helping members comply with R Ph information plan
Hospital Pharmacist Report 1997 Feb;11:1, 8
HSL6733
Applegate WB, Furberg CD, Byington RP, Grimm R Jr.
The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS)
JAMA 1997 Jan 22-29;277:(4):297
HSL19760
Wright M
1-800: is anyone listening? A prescription for effective pharmaceutical database marketing
Strategy 1997 Jan 20
www.strategyonline.ca/1997/01/20/19393-19970120/#ixzz1jOv04eau
HSL574
Bourguignon RP.
Dangers of fluoxetine.
Lancet 1997 Jan 18;349:(9046):214
HSL20467
Durand de Bousingen D
Growth-hormone CJD scandal rocks France
The Lancet 1997 Jan 18;349:(9046):189
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2805%2960939-7/fulltext#article_upsell
HSL8336
Bhutta TI, Vitry A.
Treating dysentery with metronidazole in Pakistan.
BMJ 1997 Jan 11;314:(7074):146-7
HSL20468
Ed.
And now all this
The Lancet 1997 Jan 4;349:(9044):1
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2897%2921001-9/fulltext
HSL550
Lal A, Moharana AK, Srivastava S.
Comparative evaluation of drug advertisements in Indian, British and American medical journals.
J Indian Med Assoc 1997 Jan;95:(1):19-20
HSL561
Herman AA, McCarthy BJ, Bakewell JM, Ward RH, Mueller BA, Maconochie NE, Read AW, Zadka P, Skjaerven R.
Data linkage methods used in maternally-linked birth and infant death surveillance data sets from the United States (Georgia, Missouri, Utah and Washington State), Israel, Norway, Scotland and Western Australia.
Paediatr Perinat Epidemiol 1997 Jan;11:
http://www.bmj.com/cgi/content/full/315/7106/480
HSL573
Bradley LR, Zito JM.
Direct-to-consumer prescription drug advertising.
Med Care 1997 Jan;35:(1):86-9
HSL6730
Follow-up: Boehringer Ingelheim’s promotion of Catovit (Prolintane)
MaLAM Australian News 1997 Jan-Feb;5:(1-2):3
HSL6731
Follow-up: Whitehall’s promotion of Robitussin (dextromethorphan and/or guaiphenesin and/or pseudoephedrine)
MaLAM Australian News 1997 Jan-Feb;5:(1-2):4
HSL6732
Inappropriate drug promotion in developed and developing countries: two sides of the same coin
MaLAM Australian News 1997 Jan-Feb;5:(1-2):1-2
HSL8226
Andrews EB; ISPE.
The re-emergence of epidemiology within the pharmaceutical industry.
Pharmacoepidemiol Drug Saf 1997 Jan;6:(1):57-9
HSL8332
Wechsler J.
Washington report: new year promises new initiatives, new FDA commissioner
Pharmaceutical Technology 1997 Jan;21:16, 18, 20, 22, 24, 26
HSL8333
FDA is meeting the performance goals of the Prescription Drug User Fee Act
Pharmaceutical Technology 1997 Jan;21:40
HSL520
Shear NH, Black F, Lexchin J.
Physician-detailer interaction—II.
Can J Clin Pharmacol 1997;4:(1):10
HSL524
Sanders HD.
Physician-detailer interaction—I.
Can J Clin Pharmacol 1997;4:(1):9
HSL528
Reid T.
Onsert with Canadian Family Physician questionable.
Canadian Family Physician 1997;43:613
HSL531
Quinn J, Nangle M, Casey PR.
Analysis of psychotropic drug advertising
Psychiatric Bulletin 1997;21:597-99
HSL533
Ollila E, Hemminki E.
Does licensing of drugs in industrialized countries guarantee drug quality and safety for Third World countries?
International Journal of Health Services 1997;27:309-328
HSL538
Mansfield P, Lexchin J.
MaLAM: networking for scientific integrity in drug promotion.
Essential Drugs Monitor 1997(24):5
http://web.archive.org/web/20080511183432/http://healthyskepticism.org/library/EDM/24/Page5.pdf
HSL539
Mansfield P.
Can health professionals lobby drug companies to upgrade from misleading promotion to reliable service?
Australian Prescriber 1997;20:(Supp 1):150
HSL542
Maddox LM, Katsanis LP.
Direct-to-consumer advertising of prescription drugs in Canada: its potential effect on patient-physician interaction.
Journal of Pharmaceutical Marketing & Management 1997;12:(1):1-21
HSL543
MacKowiak ED, O'Connor TW, Geller H, Nguyen J, Wilkes W.
A survey of pharmacists' and pharmacy students' attitudes toward OTC advertising
Journal of Pharmaceutical Marketing & Management 1997;12:(1):33-49
HSL546
Lexchin J.
Recent progress in drug advertising
Can Fam Physician 1997;43:1041-1042
HSL552
Jeffries JJ.
Physician-detailer interaction—II.
Can J Clin Pharmacol 1997;43:(1):10
HSL553
Additional statements from the International Committee of Medical Journal Editors.
CMAJ 1997;156:(4):571-8
http://www.cma.ca/cmaj/vol-156/issue-4/0571.htm
HSL578
Ault A.
Further controversial provisions in the bill
Lancet 1997;350:1690
HSL581
Wolfe S.
Drug advertisements and prescribing
Lancet 1997;348:1452-1453
HSL1604
Suryawati S, Santoso B.
Drug advertisements: A critical lesson for Indonesian students
Essential Drugs Monitor 1997;23:23
http://www.who.int/medicines/library/monitor/edm_23_e.pdf
HSL2105
Bischoff MB.
Successful pharmaceutical selling: Frank advice from the front lines.
New York: McGraw Hill 1997
http://www.amazon.com/exec/obidos/tg/detail/-/0786312114/qid=1124508662/sr=1-1/ref=sr_1_1/002-4340062-2313626?v=glance&s=books
HSL5427
Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW.
Methods for the Economic Evaluation of Health Care Programs
Oxford: Oxford University Press 1997
HSL6711
CMA sets rules for sale of prescribing data
Canadian Medical Association Journal 1997;156:155
http://www.cma.ca/cmaj/vol-156/issue-2/0155a.htm
HSL6712
Angell M, Kassirer JP.
Editorials and conflicts of interest
New England Journal of Medicine 1997;336:729
HSL6713
Davis P.
Managing medicines: public policy and therapeutic drugs
Buckingham, United Kingdom: Open University Press 1997
HSL6714
Erisman MD.
Editorials and conflicts of interest
New England Journal of Medicine 1997;336:729
HSL6715
Feczko JM.
Pfizer night at Boston Billiards
New England Journal of Medicine 1997;337:134
HSL6716
Gordon DA.
Intimidation of researchers by special-interest groups
New England Journal of Medicine 1997;337:1316-1317
HSL6718
Kamat VR, Nichter M.
Monitoring product movement: an ethnographic study of pharmaceutical sales representatives in Bombay, India
ABIM - An Annotated Bibliography of Indian Medicine London: Zed Books 1997
http://indianmedicine.eldoc.ub.rug.nl/root/K/55269/
HSL6719
Kiatying-angsulee N.
A participatory evaluation of the implementation of the WHO ethical criteria for medicinal drug promotion in multiple countries
Australian Prescriber 1997;20:(Supplement 1):151
www.australianprescriber.com
HSL6721
Lucas PN
Education and information: obligations and responsibilities to health care professionals and to consumers: A decade of achievement: 1996-1997 annual report
Ottawa: Pharmaceutical Manufacturers Association of Canada 1997
HSL6722
Martin JB.
Bioequivalence of levothyroxine preparations: industry sponsorship and academic freedom
JAMA 1997;277:1201
HSL6723
Molloy W, Strang DG, Wadhwa SG, Carter PA
The fine detail
Troy, Ontario, Canada: Newgrange Press 1997
HSL6724
Mongeau JG.
Weighing benefits and risks of drug to treat obesity
Canadian Medical Association Journal 1997;156:769
HSL6725
Phillips D, Marlow B.
Response to onsert
Canadian Family Physician 1997;43:1205
HSL6727
Rogers A.
EU has limited power to curb Internet drug sales
Lancet 1997;349:1895
HSL6729
Whiteside C.
Onsert with Canadian Family Physician questionable
Canadian Family Physician 1997;43:613
Page 172 of 206 pages ‹ First < 170 171 172 173 174 > Last ›
